. 2020 Dec 10;24(3):171–180. doi: 10.1093/ijnp/pyaa064

Table 4.

Secondary PD Outcome Measures: Individual Maximum or Minimum

Comparison	Overall drug-liking^a	Take drug again^b	Good effects^b	High^a	ARCI MBG^a	Bad effects^a	ARCI LSDG^a	Alertness/ drowsiness^b,c	ARCI PCAG^b	Any effects^a	Dizziness^a
Silexan 80 mg vs placebo	0.0	2.5	1.7	0.0	0.0	0.0	0.0	−3.4	0.4	1.5	0.0
Silexan 640 mg vs placebo	0.0	11.5	13.9*	1.0*	0.0	0.0	0.0	−1.4	−0.7	0.5*	0.0
Lorazepam 2 mg vs placebo	25.0***	52.3***	45.5***	44.0***	2.0***	1.0	0.5***	−19.2***	4.0***	55.0***	4.5***
Lorazepam 4 mg vs placebo	31.0***	60.0***	52.9***	51.5***	5.0***	6.0***	2.0***	−23.7***	5.6***	60.0***	22.5***
Silexan 80 mg vs lorazepam 2 mg	−24.5***	−49.9***	−43.8***	−30.0***	−1.0***	0.0	0.0***	15.8***	−3.5***	−43.5***	−3.5***
Silexan 640 mg vs lorazepam 2 mg	−14.0***	−40.8***	−31.6***	−27.0***	−1.0*	0.0	0.0**	17.8***	−4.7***	−30.5***	−3.0***
Silexan 80 mg vs lorazepam 4 mg	−29.0***	−57.5***	−51.2***	−45.5***	−4.0***	−2.5**	−2.0***	20.3***	−5.2***	−46.0***	−23.5***
Silexan 640 mg vs lorazepam 4 mg	−23.5***	−48.5***	−39.0***	−45.5***	−2.0***	−4.0**	−2.0***	22.3***	−6.4***	−32.5***	−17.0***

Abbreviations: ARCI, Addiction Research Center Inventory; LSDG, LSD Group; MBG, Morphine-Benzedrine Group; PCAG, Pentobarbital-Chlorpromazine-Alcohol Group; PD, pharmacodynamic.

Adjusted mean or median of intraindividual differences and P value; PD population, n = 34. Positive values denote higher values on applicable scale for the drug named first.

* P ≤ .05; ** P ≤ .01; *** P ≤ .001.

^aMedian differences, Wilcoxon signed rank test P values; ^bAdjusted mean differences, analysis of covariance P values.

^cMinimum effect is analyzed.